Cordoba, Argentina

Instituto Oncologico de Cordoba

Carcinoma

Renal Cell Carcinoma

Non-Small-Cell Lung Carcinoma

Urinary Bladder Cancer

Melanoma

Transitional Cell Carcinoma

Nivolumab

BMS-936558

Pembrolizumab

Erlotinib

Docetaxel

Ipilimumab

Afatinib

Vedotin

NPI-2358

Everolimus

Bristol-Myers Squibb (BMS)

Boehringer Ingelheim

Nereus Pharmaceuticals

Seagen

condition

allSponsorName

Merck Sharp & Dohme (MSD)

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.

Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).

It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Instituto Oncologico de Cordoba | Cordoba, Argentina

Site insights

Work at this site?

Active trials

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Trial sponsors